PHILADELPHIA––With new competition potentially on its way in the PCSK9 inhibitor class, Amgen’s stalwart Repatha is looking for a leg up in treating high-risk heart attack patients.
A new analysis shows that patients within the one year mark of a heart attack are at a much higher risk of a following cardiovascular event––and cholesterol-lowering Repatha is particularly effective in treating that group.
Patients treated with a Repatha-statin combo within one year after a heart attack showed a 25% risk reduction in follow-up CV events, including heart attack, death or stroke, over statins alone. In patients treated with the combo after the one-year mark, there was a reported 15% risk reduction, according to an analysis of data from Amgen’s Fourier outcomes trial set to be presented Monday at the American Heart Association Scientific Sessions.
Free Webinar
Striving for Zero in Quality & Manufacturing
Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.
Chris Kurtz, Amgen’s VP and global development and therapeutic area head for cardiovascular and metabolic, reinforced Repatha’s clinical effect on high-risk heart attack patients by intensively lowering LDL-C levels.
“It’s good that we have validation, but it’s maybe not a surprising result,” Kurtz said. “I would say there’s a growing body of evidence that there’s urgency around risk-factor control and LDL reduction and now we have tools to do it.”
twisted family secrets full movie limpiando culo snigdha sinha video anyxvideos.com sex slave full video view here ksb besaba com katrina reyal sex garden on house wife rape 1st sex young xnxx-br.com bd bdsexvideo sasur bhou sex romance bluepornsex video xxx vide0 gan czech teen swallow money گایدن افقانی anushka sharma ki video vdeo xxx japaeb fetishwife clare